February 23rd 2024
Results of a study conducted by the National Institutes of Health indicate that the Paxlovid prevented a substantial number of hospitalizations associated with COVID-19.
February 20th 2024
Planning for a post-recession scenario is essential, ensuring companies are prepared to scale up when funding permits.
February 12th 2024
The FDA granted accelerated approval to Elahere in November 2022 for adults with folate receptor-alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Entrenched and emerging hurdles alike are challenging manufacturer pricing and access strategies.
February 9th 2024
Key steps in relationship-building beyond just treatment options.
Physician Practices Post-Pandemic: Q&A with Jenny Sherak, AmerisourceBergen
Jenny Sherak, SVP & President of Specialty Physician Services at AmerisourceBergen, talks about how the needs of physician practices have evolved during the COVID-19 pandemic and what is required to navigate the shifting healthcare landscape.
Full Approval of COVID Vaccines Key to Addressing Hesitancy
The Center for Biologics Evaluation and Research’s top priority is to approve biologics license applications (BLAs) to address vaccine hesitancy, according to CBER director Peter Marks.
The Art and Science of Remote Onboarding
Nate Wible outlines how Precision Value & Health was able to virtually onboard 58 new employees in the 12-month span from March 2020 to March 2021.
Betting on Its Base in Virology
How Gilead readied remdesivir for the COVID challenge.
Scientific Rigor, Urgent Action
Inside Regeneron’s monoclonal antibody development to treat COVID.
Meeting the Crisis Head-On
Past lessons, strong resolve, and complex coordination propel J&J’s vaccine efforts.
Innovation in High Gear
Thrust into a commercial-stage company in just months, Moderna moves full steam ahead.
Bonds Old and New to the Rescue
College roommates, industry partnerships help bring Pfizer vaccine to fruition.
2021 Pharm Exec Top 50 Companies
Pharm Exec’s latest listing of the top global biopharma sales producers captures the critical business and public health balancing act that was required in the Year of COVID—reinforcing the staying power of building brand value while championing medical innovation.
Pharm Exec at 40 (1997-1999)
Looking Back at 1997–1999.
Science is Underrated
Combined powers of synbio and biopharma point to bright future for industry.
Moving Beyond Traditional Approaches to Alzheimer’s Disease
The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.
Biden Budget “Wish List” Maps FDA, Healthcare Priorities
Biden administration supports a notable increase in funding for public health and research as a lead priority for the coming year.
Developing a “Diversity Mindset” for Change in Pharma
Developing a diversity mindset may begin at the top levels of the organization, but building diversity into the entire drug development life cycle ensures that it is an ongoing priority and a natural requirement of engaging with external stakeholders.
Are We Forgetting to Develop Vaccines for Diseases other than COVID?
It's time to apply the same COVID-19 urgency to other devastating diseases, such as Alzheimer’s, write Andrea Pfeifer and William Mobley.
Vaccine Makers Ramp Up Production, Donations to Protect IP
Biopharma companies’ efforts to promote “vaccine equity” and “dose sharing” also aim to limit challenges to international patent protections.
The Rise of Longevity Therapeutics
The field of longevity therapeutics — with the goal “of not just adding years to life but adding life to years” — is already disrupting the medical industry, writes Marco Quarta.
Biopharma Q1 Earnings: The Impact of COVID-19
The recent flurry of Q1 earnings reports offer a unique opportunity to assess the real-time impacts of COVID-19 on the sector.
Executive Search in the New Normal
Nick Stephens talks to Pharm Exec about how the highs and lows of the executive search business in the last 12 months.
China: The Giant Has Awoken
With a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.
Promoting Sustainable Access to Quality Health Care
Elizabeth (EJ) Ashbourne, Executive Director of the Partnership for Quality Medical Donations (PQMD), discusses the role of the organization in advancing global health and highlights the benefits offered to members of the pharma industry.
Blockchain, COVID-19 and the Pharmaceutical Supply Chain
Hannah Schofield and Lavan Thasarathakumar discuss what blockchain is, how it could help improve pharmaceutical supply chains, and the COVID-19 vaccine supply chain in particular, and touches on where we are already seeing blockchain technology being used in this area.
Pharm Exec at 40 (1994-1996)
Looking Back at 1994–1996.
Better Supply Chains Can Better Tackle Threats to Public Health
To effectively combat the looming threat of antimicrobial resistance, we must prioritize working together to strengthen and more responsibly manage global supply chains.
Pharma Prices & Patents Under Attack
The drive for “vaccine equity” around the world is bolstering efforts to limit patent protections on innovative medicines and vaccines to combat the global pandemic.
Pandemic Highlights Need for Advanced Pharma Manufacturing
A NASEM report for CDER outlines strategies to modernize pharmaceutical manufacturing to ensure reliable access to high-quality drugs, particularly in response to disruptions caused by the pandemic.
The Importance of Collaborative Business Models for Drug Development
Insights and examples of how collaborative efforts can lead to the development of innovative therapies that target unmet patient needs.
SPBMs: Impact on Accessibility & Affordability of Gene Therapies for Rare and Orphan Diseases
The introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.
The Future of Telehealth: Evolving COVID Perspectives Offer Clues
New data comparing past vs. present experience with telemedicine during the pandemic uncovers insight on how patients, doctors, and payers view the market post-COVID.
Silver Linings of a Global Health Crisis: A New Path Forward for Pharma Media Professionals
at some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?
2 Commerce Drive Cranbury, NJ 08512